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Abstract
Ulcerative colitis (UC) is frequently treated with 5-ASA in active disease or to maintain remission. As dietary fibres binds 5-ASA in vitro, we wanted 
to investigate if a daily supplement of 30 ml of Isphagula Husk in patients with UC in remission or relapse affects disease activity and urinary excretion 
of 5-ASA.
It is a paired intervention study (trial I) and randomised controlled trial (trial II). The participants with UC in remission received 30 ml of fibre/day  
(trial I). Participants with relapsing UC were randomised to either 30 ml of fibre or blended breadcrumbs for two-three months (trial II).
The main outcome measures is C-reactive protein and 24 hours’ urine collection of total 5-ASA (trial I). In trial II the disease activity was determined by 
Inflammatory Bowel Disease Questionnaire (IBDQ) and Simple clinical colitis activity index (SCCAI) questionnaires.
22 participants with UC in remission and 12 with relapsing UC were included. In trial I no significant effect of fibre on CRP or on disease activity was 
found, whereas a decreased urinary excretion by a median of 6.3 percentage point (range: -50.6-33.6; p=0.03) of total 5-ASA was found. No significant 
differences were found between fibre and placebo groups in trial II. 
A decreased urinary excretion of total 5-ASA was seen in patients with UC in remission, but not in patients with relapsing UC. The number of patients 
was low and different factors could affect the results, but the results confirm that the in vitro results can be reproduced in patients.
Keywords: Ulcerative colitis; Dietary fibre; 5-Aminosalicylic acid (5-ASA); Isphagula Husk
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Introduction
Ulcerative colitis (UC) is treated with 5-aminosalicylic acid (5-ASA) in 
mild to moderate disease and maintains remission. How 5-ASA affects 
the disease is not known, but it is assumed that it exerts its effect from 
colon lumen. For this reason it is attractive to increase the intraluminal 
concentration of 5-ASA in the colon, by a reduced absorption in the intestine 
[1,2]. Such an effect may be obtained by binding of 5-ASA to dietary fibres. 
The fibre Isphagula Husk, which consists of psyllium from the Indian plant 
‘Plantage Ovata’, binds 5-ASA more efficient than wheat bran, citrus-pectin 
and wheat flour in vitro [3].
Isphagula Husk is moderately fermented in colon and consequently 5-ASA 
may be liberated and the intraluminal concentration of 5-ASA in colon may 
thereby be increased [4]. Also the side effects of 5-ASA may be decreased 
because they are mainly attributed to the absorbed fraction. This binding 
capacity might thereby be a therapeutic gain in the treatment of UC with 
5-ASA. Low compliance with intake of medicine is observed also among 
patients with UC [5], and that increases the attraction to decrease the need 
for medicine. Kidney damage by 5-ASA is rare [6], but this only add to the 
wish for a non-toxic dietary way of decreasing the absorption of 5-ASA. 
The purpose of this study were to investigate if a daily supplement of 
Isphagula Husk in patients with UC in remission or relapse affects disease 
activity and urinary excretion of 5-ASA.
Methods and Materials
Trial Design
Trial I is a paired intervention study, whereas trial II is a randomized double-
blind placebo-controlled trial, where randomisation was conducted after 
collection of baseline data to either fibre or placebo using sealed envelopes 
with tinfoil to ensure blindness.
All patients were recruited consecutively at the outpatient clinic at Aalborg 
University Hospital. 
Inclusion and Exclusion Criteria
Adult patients (18-75 years) with a diagnosis of Ulcerative colitis were 
suitable for inclusion in the trials.
In trial I, patients with inactive UC with a ‘Simple clinical colitis activity 
index’ (SCCAI) score [7] of 0-3 were recruited.
In trial II, patients with active UC with an SCCAI score of 4-10 were 
recruited.
All patients were in a stable-dose, oral treatment with 5-aminosalicylic 
acid (5-ASA) for minimally one month before inclusion and throughout the 
studies. Rectal 5-ASA was allowed and was to be stabile as the oral dose 
of 5-ASA. 
Exclusion criteria in both trials included the use of steroids, patients 
with impaired renal or liver function, use of gluco-corticosteroids 
within 1 month prior to study entry or during study period, ileostomy, 
pregnancy, coeliac disease and not being able to communicate in Danish.
Patient Recruitment
In both trials, suitable patients were recruited at their regular control visits 
in the out-patient clinic. Furthermore, potential patients were searched 
for in the departments’ patient registry – a registry of all patients with 
gastrointestinal diseases in the North region of Denmark. These were 
contacted by phone. All gave informed consent.
Trial Endpoints
The primary endpoint in trial I was the change in CRP and the secondary 
endpoint was the change in total urinary 5-ASA excretion in patients with 
UC in remission. The participants are their own controls in trial I.
In trial II, the primary endpoint was change in SCCAI and Inflammatory 
Bowel Disease Questionnaire (IBDQ) and the secondary endpoint was the 
change in total urinary 5-ASA excretion in patients with UC in relapse. In 
trial II the control and intervention groups are compared.  
The SCCAI includes questions regarding bowel frequency (day and night), 
urgency of defecation, blood in stools, general wellbeing, and extra colonic 
manifestations. A score was given for each of the questions and a final score 
between null and 19 is given. The higher the score, the more and worse the 
symptoms.
Trial Protocol
In trial I, patients received a box with Isphagula Husk and in trial II patients 
received a box with Isphagula Husk or blended breadcrumbs. In both trials 
the patients were supposed to take an amount of 30 ml powder per day 
mixed with food or a cold beverage for one week (trial I) or two or three 
months (trial II) at the same time as proceeding with 5-ASA in unchanged 
dose. Before and at the last day with powder intake a blood sample was 
collected from the patients. At the same point of time, the patients collected 
a faeces sample and urine for 24-hours.
The box included more powder (Isphagula Husk or blended breadcrumbs) 
than the patients needed and compliance was measured by weighing the 
amount of returned powder.
In both trials, all patients remained on an unrestricted diet and stable 
maintenance therapy for their UC throughout the trial, but were asked to 
keep everything as constant as possible.
Intake of dietary fibre in trial II was assessed by using a food frequency 
questionnaire with focus on fibre containing food items, especially fibre 
rich food items. The questionnaire was developed by the authors for this 
trial and therefore not validated.  
Measurement of Urinary 5-ASA Excretion, CRP and 
f-calprotectin
The total urinary 5-ASA excretion was measured as the sum of 5-ASA and 
its metabolite acetyl-5-ASA in urine. The method of analysis was based 
on liquid chromatography using an Agilent 1100 series chromatograph 
(Agilent Technologies, Palo Alto, CA, USA) equipped with a Quatpump, 
a degasser, a column oven, an autosampler, a DAD UV detector operated at
Enliven Archive | www.enlivenarchive.org
 
 
2016 | Volume 3 | Issue 13
240 nm and a fluorescence detector operated with excitation at 315 nm and 
emission at 430 nm. The reversed phase column was a Xterra MS (Waters, 
Milford, MA, USA) C18, 100 x 2.1 mm with 3.5 µm particles. The mobile 
phase consisted of acetonitrile + 0.05 M sodium phosphate pH 6.2 (40:60 
v/v) delivered with a flow rate of 0.25 ml/min. The column was maintained 
at 30°C.
Urine was either measured directly after mixing and centrifugation (for 
5-ASA using fluorescence detection) or after dilution 100 times (for acetyl-
5-ASA using UV at 240 nm).
Measurement of CRP and f-calprotectin was conducted as part of the routine 
of the laboratory methodology (accredited laboratory).
For measurement of f-calprotectin all patients were given a set containing a 
little spoon, a glass and a franked envelope. All patients were instructed to 
send the test to the laboratory the day it was taken.
Statistical Analysis
The Mann-Whitney rank sum test and the Wilcoxon signed rank sum test 
were used for unpaired and paired comparisons respectively. Kruskal-Wallis 
and Friedmans test were used for excretion of 5-ASA in the urine in trial II 
due to three measurements.
The treated as protocol population was defined as a subset of all randomised 
patients excluding all patients with major protocol violations as well as 
participants who did not complete the study.
Quantitative variables are described using median (range) in trial I and 
range and percent in trial II whereas qualitative variables are described by 
frequency in both trials.
Statistical analysis was conducted using GraphPad Prism 5.
Ethics
The trials were approved by the regional ethical committee (case number 




Trial I: Of 64 patients, 25 declined or could not be contacted and 17 did 
not meet the inclusion criteria. A total of 22 patients were included. Two 
patients were excluded from the final analysis because of change in the 
dose of medicine or relapse, and in addition, two patients did not show 
up for the follow-up visit. A total number of 18 patients were eligible for 
analysis. Thirteen patients took Asacol and three patients took Mesasal. Two 
patients took Pentasa.  Table 1 shows the baseline characteristics for trial I.
BMI = Body mass index, SCCAI, Simple clinical colitis activity index, CRP = C-reactive protein. 
Quantitative variables are described using median (range) and qualitative variables are described by frequency (%).
* Estimated from18 participants. ** Estimated from 17 participants.
Total, n Intention-to-treat (n=22) Per protocol (n=18) 
Age, years 46.5 (21.0-71.0)  48.0 (21.0-71.0)
Sex, n   
     Women 15 (68) 13 (72)
     Men 7 (32) 5 (28)
BMI, kg/m2 24.6 (19.1-31.8) 24.9 (19.1-31.8)
SCCAI, point 1.0 (0.0-3.0) 1.0 (0.0-3.0)
Disease extent, n   
     Proctitis 4 (18) 3 (17)
     Proctosigmoiditis 3 (14) 3 (17)
    Left sided colitis 2 (9) 2 (11)
    Extensive colitis/pancolitis 13 (59) 10 (56)
CRP, mg/L 1.3 (0.49-15.0) 1.5 (0.6-15)
Type of medicine, n   
     Pentasa® 2 (9) 2 (11)
     Asacol® 17 (77) 13 (72)
     Asacol® + Mesasal® 3 (14)   3 (17)
Dose of medicine, mg/day   
     5-ASA 4000 (800-6000) 3700 (800-6000) **
Total urinary 5-ASA excretion, %   
     Pentasa® 38 (13.5-62.5) * 38 (13.5-62.5) *
     Asacol® 28.4 (5.7-64.7) 28.4 (5.7-64.7)
Medicine compliance, % 100 (89-100) 100 (92-100)
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Trial II:  A total of 12 patients were randomly assigned to Isphagula Husk 
(n=8) or placebo (n=4). One patient was excluded from the final analysis due 
to change in the dose of medicine, and additionally two patients never started 
their assigned treatment and one patient did not want to continue due to lack 
of effect. A total number of eight participants were eligible for analysis - four 
Clinical Outcomes Trial I
After one week with fibre supplement the primary endpoint, CRP, decreased 
with 7.7 mg/L (p=0.27). Total urinary excretion of 5-ASA, decreased 6.3 
percentage point (range: -50.6-33.6) (p=0.03) in absolute values (treated 
as protocol population). Post hoc analysis without the patient, who was 
noncompliant with the medicine (n=17) showed an even more significant 
decrease of 6.3 percentage point (range: -50.6-33.6) (p=0.008) in total 
urinary excretion of 5-ASA. Data is shown in table 3 and figure 1 and 2.
from the intervention group and four from the placebo group. All the patients 
in the intervention group took Asacol. In the placebo group, two patients 
took Asacol and one patient took Mesasal. Only one patient took Mezavant. 
There were no significant differences between the two treatment groups at 
baseline (Table 2).
 Fiber group Placebo group p-value
Total, n 8 (4) 4   -
Age, years 23-54 (23-33) 35-53 0,35 (0,029)
Sex, n   
-     Women 4 (1) 2
     Men 4 (3) 2
BMI, kg/m2 19,6-27,7 (20,3-26,6) 20,5-25,4 0,67 (1,0)
FFQ, g/day 9-26 (16-26) 13-29 0,39 (1,0)
IBDQ, point 135-199 (158-199) 133-196 0,67 (0,38)
SCCAI, point 4-8 (4-8) 10-Apr 0,93 (0,56)
f-calprotectin, μg/g 29-2444 (29-2444) 78-2924 0,51 (0,69)
CRP, mg/L 0,4-9,9 (0,4-7,5) 0,4-12 0,78 (0,56)
Disease extent, n   
-
     Proctitis 3 (2) 1
     Proctosigmoiditis 1 (0) 1
    Left sided colitis 2 (1) 1
     Extensive colitis/pancolitis 2 (1) 1
Type of medicine, n:   
-
     Mezavant® 0 (0) 1
     Asacol® 7 (4) 2
     Asacol® + Mesasal® 1 (0) 1
Dose of medicine, mg/day 2400-4500 (2400-4000) 2400-4800 0,93 (0,77)
Total urinary 5-ASA excretion, % (0,5-27,1) * 2,7-26,0 (0,89)
Medicine compliance, % *** 43-100** (94-100) 68-100*** 0,48 (0,24)
BMI = Body mass index, FFQ = Food frequency questionnaires, IBDQ = Inflammatory bowel disease questionnaire, SCCAI = Simple clinical colitis 
activity index, CRP = C-reactive protein.
Quantitative variables are described using range and qualitative variables are described by frequency.
Data are estimated as intention-to-treat, and in brackets are shown data as treated as protocol.
* n=5. **n=6. *** n=3.
Clinical outcomes (trial I). 
 Difference p-value
CRP, % (n=18) 7.7 0.27
Total urinary 5-ASA excretion, % (n=18) 6.3 0.03
Total urinary 5-ASA excretion, % (n=17) 6.3 0.008
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Figure 1  Urinary 5-ASA excretion – per protocol analysis











Figure 1: Total urinary 5-ASA excretion before and after seven days fiber intake according to treated as protocol analysis (n=18) (p=0.03). 
a) Shows the excretion for each single patient. 
b) Shows the both the median before (28.4 %) and after (17.5 %) for the excretion (range 50.6-33.6 %).
Figure 2: Total urinary 5-ASA excretion before and after seven days fiber intake according to post hoc analysis (n=17) (p=0.008). 
a) Shows the excretion for each single patient. 
b) Shows the both the median before (29.4 %) and after (16.4 %) for the excretion (range 50.6-33.6 %).
a) Total Urinary 5-ASA excretion (%), n=18
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Treatment Compliance in Trial I
At follow-up, 15 participants delivered the remaining fibre, thus resulting in 
a compliance with fibre intake of 104 (87-140) %. At follow-up all patients 
took the prescribed dose of medicine.
Clinical Outcomes in Trial II
In trial II no significant changes were found neither within nor between 
fibre and placebo group with in respect to IBDQ and SCCAI score, faeces 
samples, and excretion of 5-ASA and ac-5-ASA, (Table 4).
The results for disease activity score at baseline (1.) and follow-up (2. or 3. if three measurements) together with the effect over time (E).
Patient IBDQ SCCAI F-calprotectin Total urinary 5-ASA excretion
5 1 2 E 1 2 E 1 2 E 1 2 3 E
192 165 ↓ 8 8 ↔ 2444 472 ↑ 0.5 0 0.8 ↓
10 199 189 ↓ 5 5 ↔ 98 116 ↓ 26.7 18 21 ↑
11 158 175 ↑ 4 3 ↑ <30 <30 ↔ 27.1 27.3 17.2 ↑
12 161 199 ↑ 5 2 ↑ 283 152 ↑ 7.7 7.9 16.5 ↓
3 133 166 ↑ 6 5 ↑ 2924 614 ↑ 2.7 3.7 0.6 ↑
4 142 122 ↓ 10 11 ↓ 1076 >3600 ↓ 14.9 11.5 11.5 ↑
7 161 189 ↑ 7 2 ↑ 115 24 ↑ 23.9 36.6 44.7 ↓
9 196 198 ↑ 4 4 ↔ 78 233 ↓ 26 33 33.2 ↓
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Treatment Compliance in Trial II
At follow-up all patients delivered the remaining powder, thus resulting in a 
compliance with intake of fibre of 72-117 % (range) and intake of breadcrumbs 
of 61-100 % (range). At follow-up all patients in the fibre group took the 
prescribed medicine, whereas the medicine compliance was 90.6-100 % 
(range) in the placebo group. The patients in the fibre group had an intake of 
dietary fibre of 16-26 g/day at baseline and 21-37 g/day at follow up whereas 
the intake was 13-29 g/day at baseline and 22-26 g/day at follow up in the 
placebo group (data as range) measured by food frequency questionnaire.
Discussion
In this study we examined the binding effect of 5-ASA to Isphagula Husk 
by examining urinary excretion of 5-ASA in patients with UC in remission 
and relapse (trial I and II). We also examined the effect on disease activity in 
patients with UC in remission and relapse (trial II). 
In trial I we observed no changes in CRP level over the study period (p=0.27), 
whereas a significant decrease of 6.3 percentage point in the amount of 
5-ASA excreted in the urine was found in patients with UC in remission 
(p=0.03). The reason that less 5-ASA was excreted in the urine may be due to 
that a binding effect between 5-ASA and Isphagula Husk is seen and 5-ASA 
may as a consequence be transported to the colon together with Isphagula 
Husk. In the colon Isphagula Husk is moderately fermented Eswaran et al. 
[4] and 5-ASA may be liberated and the intraluminal concentration in colon 
may thereby be increased.
I trial II no changes was found in active UC in respect to changes in disease 
activity and excretion of 5-ASA in the urine, but it seems that patients in 
the fibre group did not worsen over time. The possible coherence between 
disease activity and fibre intake may be due to increased production of short 
chain fatty acids in the colon [8]. The risk of errors of type 2 is, however, 
very large due to the small number of patients included in trial II, and this 
may be the reason that we see a decreased excretion of 5-ASA in trial I and 
not in trial II.
In trial I and II several factors could have influenced the results. E.g. both 
trials included patients with different extensions of colitis and it is impossible 
to know if the colonic absorption of fibre and 5-ASA differ because of that. 
One patient in trial II took Mezavant, which have a more distal 5-ASA 
release than e.g. Asacol and Pentasa. The different release systems could 
have influenced the results [1,9]. 
 
Most patients had very small variations in the CRP-concentrations - the 
largest decrease was 2.0 mg/L and the largest increase was 2.7 mg/L. In 
these well-treated patients, one could hardly expect to detect a difference in 
disease activity unless the number of patients was very large. 
Compliance turned out to be satisfying in this study, although methods 
for measurement are imprecise. The intake of fibre in trial I reached a 
compliance rate at 104 %, which illustrated that the patients used a larger 
amount of powder than instructed.
Ingestion of 30 g/day of Isphagula Husk over 4 weeks has shown a decrease 
in pH of 0.5 in colon [10]. Also pH values of 2.3-4.3 were found in patients 
with active UC, only in three out of seven patients, though. These were the 
patients with the most active disease. In the rest of the patients pH values 
of 5.0 and 7.4 were found, and these are considered normal [11]. Although 
pH has a large impact on the absorption of 5-ASA in colon with a maximum 
absorption at pH 5.5, this is hardly relevant to the effect on urinary excretion 
as most of the absorption takes place in the small intestine, where dietary 
fibres do not alter pH.
Also the side effects of 5-ASA may be decreased because they are mainly 
attributed to the absorbed fraction. This binding capacity might therefore be 
a therapeutic gain in the treatment of UC with 5-ASA.
Intake of dietary fibre was determined using a food frequency questionnaire, 
which was constructed for trial II in particular and therefore not validated 
in other studies. 
The participants were asked not to change their intake of dietary fibre 
and fibre rich food items while participating in trial II. Despite this, three 
participants in the fibre group and two in the placebo group increased their 
fibre intake, while two in the placebo group decreased their intake. Only one 
patient in the fibre group had a stable intake of fibre. Other sources of fibre 
than Isphagula Husk may have an impact on the absorption of 5-ASA, but 
the importance of this is not known [3], although other fibres had a much 
lesser binding capacity for 5-ASA in vitro.
The accuracy of the urine collection is always a crucial point, and several 
patients in both trials had very small amounts of total urine, but this was 
equally distributed in both randomization groups although adding to the 
variance in a small study. The variability of 5-ASA excretion in the urine 
has earlier been seen to increase with 24-36 % after Asacol, 25-37 % after 
Pentasa and 33-57 % after Mesasal intake [5,12,13]. A decrease of 6.3 %, as 
seen in this study, could therefore be a natural variation and maybe not an 
effect of the dietary fibre intake.
Conclusion
In patients with quiescent UC a decreased excretion of 5-ASA was found, 
but this was not seen in eight patients with active UC, possible due to the 
small number of participants. No effects on disease activity was found in 
either trial, but participants in the placebo group in trial II seemed to have 
worsened activity whereas participants in the fibre group did not worsen, 
generally seen from SCCAI, IBDQ, faecal calprotectin and CRP.
From these trials it seems that a fibre supplement does not worsen patient’s 
symptoms, and this may allow for larger studies investigating the potential 
positive effect of fibre supplement on disease activity or risk of flare ups.
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